Tulane University Hematology and Medical Oncology

Topics

• Prostate Cancer Treatment and Research 290
• Hemophilia Treatment and Research 83
• Prostate Cancer Diagnosis and Treatment 61
• Radiopharmaceutical Chemistry and Applications 24
• Chronic Lymphocytic Leukemia Research 19
• Cancer Cells and Metastasis 17
• Estrogen and related hormone effects 14
• Lymphoma Diagnosis and Treatment 13
• PARP inhibition in cancer therapy 12
• Platelet Disorders and Treatments 11
• Bone health and treatments 10
• Breast Cancer Treatment Studies 10

Most cited

1. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

   The New England journal of medicine · 2021 · 2,264 citations · Oliver Sartor

2. Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.

   Journal of the National Comprehensive Cancer Network : JNCCN · 2024 · 560 citations · Erica Stringer-Reasor

3. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

   Journal of the National Comprehensive Cancer Network : JNCCN · 2022 · 759 citations · Erica Stringer-Reasor

4. NCCN Guidelines® Insights: Breast Cancer, Version 4.2023.

   Journal of the National Comprehensive Cancer Network : JNCCN · 2023 · 390 citations · Erica Stringer-Reasor

5. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial.

   Lancet (London, England) · 2024 · 270 citations · Oliver Sartor

6. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.

   The Lancet. Oncology · 2023 · 275 citations ·